2019
DOI: 10.1210/clinem/dgz028
|View full text |Cite
|
Sign up to set email alerts
|

Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome

Abstract: Context Women with polycystic ovarian syndrome (PCOS) have decreased growth hormone (GH), which can result in increased visceral adiposity (VAT) and impaired vascular function. GH-releasing hormone, a dipeptidyl peptidase-4 (DPP4) substrate, stimulates GH secretion. Objective We tested the hypothesis that DPP4 inhibition increases GH and improves glucose levels and vascular function in women with PCOS. … Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
23
0
1

Year Published

2020
2020
2022
2022

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 31 publications
(24 citation statements)
references
References 46 publications
0
23
0
1
Order By: Relevance
“…At 1 month, treatment with sitagliptin increased GLP-1 levels and reduced the peak glucose response to OGTT (-17.2 mg/dL), significantly reduced the visceral fat (from 1141.9 ± 700.7 to 1055.1 ± 710.1 g) and increased growth hormone half-life (from 13.9 ± 3.6 to 17.0 ± 6.8 min). 73 It also reduced the level of cholesterol (from 168.8 mg/dL ± 26.3 to 162.5 ± 22.2 mg/dL) and improved IR 74 (Table 2).…”
Section: Sitagliptinmentioning
confidence: 88%
See 1 more Smart Citation
“…At 1 month, treatment with sitagliptin increased GLP-1 levels and reduced the peak glucose response to OGTT (-17.2 mg/dL), significantly reduced the visceral fat (from 1141.9 ± 700.7 to 1055.1 ± 710.1 g) and increased growth hormone half-life (from 13.9 ± 3.6 to 17.0 ± 6.8 min). 73 It also reduced the level of cholesterol (from 168.8 mg/dL ± 26.3 to 162.5 ± 22.2 mg/dL) and improved IR 74 (Table 2).…”
Section: Sitagliptinmentioning
confidence: 88%
“…At 1 month, treatment with sitagliptin increased GLP-1 levels and reduced the peak glucose response to OGTT (-17.2 mg/dL), significantly reduced the visceral fat (from 1141.9 ± 700.7 to 1055.1 ± 710.1 g) and increased growth hormone half-life (from 13.9 ± 3.6 to 17.0 ± 6.8 min). 73 who had previously received liraglutide 3.0 mg for obesity management, were randomly allocated to a combination of either metformin 1 g BID and sitagliptin 100 mg/day or metformin 1 g BID alone. The results showed women treated with metformin regained 4.5 ± 2.5% (4.7 ± 2.7 kg, p = 0.002) of their weight compared to 0.8 ± 0.6% (0.9 ± 2.5 kg, p = 0.147) in the combination group.…”
Section: Evidence For the Therapeutic Potentials Of Dpp-4 Inhibitors mentioning
confidence: 99%
“…A double-blind crossover study tested the effect of sitagliptin on blood glucose levels and visceral fat (VAT) in women with PCOS, and demonstrated a reduction in the maximal glucose response to the oral glucose tolerance and VAT. 75 In a pilot randomised study that examined sitagliptin as a potential treatment option in metformin intolerant PCOS patients, sitagliptin improved β-cell function (HOMA-B) and insulin sensitivity. 76 In an animal study, sitagliptin reduced fasting blood glucose, lowered androgen levels and improved ovarian fibrosis in rats with PCOS.…”
Section: Treatment Options For Managing Metabolic Comorbiditiesmentioning
confidence: 99%
“…The 58 RCTs were published until 2020, of which 35 RCTs (60.3%) 23,25–27,30–35,40,41,44–46,48,49,51–53,57,58,61,67–70,72,74,76,79–81 diagnosed PCOS based on the Rotterdam criteria 2003 85 ; nine (15.5%) RCTs 24,39,43,47,50,55,56,71,73 used the National Institute of Health 1990 (NIH, NICHD) criteria 86 while no diagnostic criteria were given for the rest of the RCTs (Table 2).…”
Section: Resultsmentioning
confidence: 99%
“…Three (5.2%) RCTs assessed liraglutide compared with liraglutide added to metformin 45–47 . Two (3.4%) RCTs examined sitagliptin compared with placebo 30,34 . Two (3.4%) RCTs assessed exenatide compared with metformin 53,80 .…”
Section: Resultsmentioning
confidence: 99%